Potential impact of 5 years of ivermectin mass drug administration on malaria outcomes in high burden countries.

Marathe, Achla; Shi, Ruoding; Mendez-Lopez, Ana; Hu, Zhihao; Lewis, Bryan; Rabinovich, Regina; Chaccour, Carlos J; Rist, Cassidy

Marathe, Achla; Shi, Ruoding; Mendez-Lopez, Ana; Hu, Zhihao; Lewis, Bryan; Rabinovich, Regina; Chaccour, Carlos J; Rist, Cassidy.

Afiliação

Marathe A; Network Systems Science and Advanced Computing Division, Biocomplexity Institute, University of Virginia, Charlottesville, Virginia, USA.
Shi R; Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
Mendez-Lopez A; Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
Hu Z; Department of Preventive Medicine, Public Health and Microbiology, Autonomous University of Madrid, Madrid, Spain.
Lewis B; Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain.
Rabinovich R; Department of Statistics, Virginia Tech, Blacksburg, Virginia, USA.
Chaccour CJ; Network Systems Science and Advanced Computing Division, Biocomplexity Institute, University of Virginia, Charlottesville, Virginia, USA.
Rist C; Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain.

BMJ Glob Health ; 6(11)2021 11.

Article em En | MEDLINE | ID: mdl-34764146

Assuntos

Malária; Administração Massiva de Medicamentos; Análise Custo-Benefício; Humanos; Ivermectina/uso terapêutico; Malária/tratamento farmacológico; Malária/epidemiologia

Palavras-chave

health economics; malaria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Administração Massiva de Medicamentos / Malária Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: BMJ Glob Health Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google